The Life Sciences IPOs + Capital Markets team advised the underwriters of Renalytix AI plc’s (NASDAQ: RNLX) global offering of an aggregate of 11,000,000 new ordinary shares, including 5,485,000 American Depositary Shares (“ADSs”) at a price of US$13.50 per ADS and 30,000 ordinary shares at a price of £5.37 per ordinary share (at an exchange rate of GBP:USD 1:1.2563). In addition, the underwriters elected to purchase an additional 806,750 ADSs at the Global Offering price of US$13.50 per ADS, bringing the total gross proceeds of the Global Offering to approximately US$85.1 million (equivalent to approximately £67.8 million at the exchange rate used in the Global Offering prospectus).
RenalytixAI is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs.
The Goodwin team was led by Thomas Levato, Audrey Leigh and included Andrew Harrow, Janet Andolina, Matthew Dunay, Robert Young, Julie Tibbets, Steven Tjoe, Roger Cohen, Nikhil Sethi, Alexandra Denniston and Ettore Santucci.
For more details, read the press release.